PMDA drug package insert
ワソラン錠40mg
PMDA Prescription drug · エーザイ株式会社 · package insert Feb 27, 2025
Key facts
| Brand names | ワソラン錠40mg |
|---|---|
| Nonproprietary names | ベラパミル塩酸塩 |
| Companies | 製造販売元／エーザイ株式会社, 販売元／ヴィアトリス製薬合同会社 |
| Product type | Prescription drug |
| Therapeutic category | Ca++拮抗性不整脈・虚血性心疾患治療剤 |
| Therapeutic category codes | 872171 |
| YJ codes | 2171008F1070 |
| Approval numbers | 21800AMX10423000 |
| Package insert edition | 第4版 |
| Package insert date | Feb 27, 2025 |
| PMDA document key | 170033_2171008F1070_2 |
| PMDA company code | 170033 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: